Due to the progressive nature of type 2 diabetes, many patients need insulin as add-on to
oral antidiabetic drugs (OADs) in order to maintain adequate glycemic control. Insulin …

Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell
responsiveness to glucose. An extensive clinical program involving approximately 22,000 …

Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally
active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by …

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy
have been widely confirmed in a large body of clinical studies of up to 2 years' duration in …

Vildagliptin is a potent and selective oral dipeptidyl peptidase‐4 inhibitor that improves
glycaemic control in patients with type 2 diabetes mellitus (T2DM) by increasing both α‐and …

As part of an extensive clinical development programme in patients with type 2 diabetes
(T2DM), vildagliptin 50 mg once daily and twice daily, and 100 mg once daily have been …

Aim: Analyzing safety aspects of a drug from individual studies can lead to difficult-to-
interpret results. The aim of this paper is therefore to assess the general safety and …

Vildagliptin is an oral incretin enhancer that acts to increase active levels of the incretin
hormone glucagon‐like peptide‐1 (GLP‐1) by inhibiting the dipeptidyl peptidase‐4 enzyme …

Vildagliptin is a selective and potent dipeptidyl peptidase-4 inhibitor that improves glycemic
control by inhibiting the degradation of both endogenous glucagon-like peptide-1 and …

Several new oral antidiabetic agents, known as 'gliptins' or 'enzyme dipeptidyl peptidase‐IV
(DPP‐4) inhibitors', have been developed for the treatment of type 2 diabetes and a key …